Shows promise in early clinical testing, outperforms existing ART and provides results within minutes
Scientists in Singapore have developed a potentially game-changing rapid antigen test (ART) technology to diagnose COVID-19. Using proprietary kit amplification technology, human saliva can be self-managed or detected at the point of care for SARS-CoV-2 virus. Its sensitivity is higher than the current ART detection and is close to laboratory-based polymerase chain reaction ( PCR) test.
This technique is called the Parallel Amplified Saliva Rapid Point-of-Care Test (PASPORT), which produces results in minutes without the need for additional equipment or specially trained personnel.
The invention originated from the Duke-National University of Singapore School of Medicine, Singapore General Hospital (SGH) and the National Cancer Center Singapore (NCCS) (a joint member institution of SingHealth Duke-National University of Singapore Academic Medical Center) and the National University of Singapore. Research cooperation (National University of Singapore).
Duke-NUS and SingHealth have applied for intellectual property protection for the invention and signed a license agreement with Singapore company Digital Life Line Pte Ltd. The inventor hopes that through close cooperation with business partners, the product can be launched as soon as possible to meet the healthcare needs of Singapore and other regions.
Singapore is ready to be...
The laboratory is in such an era...
The lasting benefits of decentralization
For the automation product portfolio, we set
Is Singapore ready to become the world?
India develops artificial intelligence tools to detect carbon dioxide
China pays attention to the next generation
BioNTech will build the first South E
WHO lists China's national medicine COVID-1
Does the Asia-Pacific region focus on vigilance and preparation for new and existing infectious diseases?
1 North Bridge Road, #08-08 High Street Centre, Singapore 179094 Email: communications@biospectrumasia.com
© 2021 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer
Web interface conceived and supported by SCI Knowledge Interlinks